Authorities Tighten Oversight of Essential Medicine Supplies

Mauritian health authorities have intensified efforts to monitor the country's medicine supply chain amid recent concerns over the availability of certain essential treatments. Officials from the Ministry of Health have held a series of meetings this week to review current stock levels, identify potential risks, and accelerate procurement procedures to ensure patients continue receiving necessary medications.

The increased monitoring follows public concern about supplies of specific drugs, including Fluorouracil, a chemotherapy medication, and treatments prescribed for people living with diabetes. While the ministry acknowledges challenges affecting some specialized medicines, it maintains that the public healthcare system is not experiencing widespread shortages.

According to health officials, oncology medications remain vulnerable to global supply chain disruptions, with international shortages, delayed deliveries, unsuccessful procurement tenders, and the relatively small size of the Mauritian market making sourcing more difficult.

Regarding diabetes care, the ministry stated that there is no nationwide shortage of Vildagliptin. Temporary supply pressures reported at certain healthcare facilities have been linked to higher-than-expected demand in specific regions, which authorities say is partly due to increased prescribing patterns.

To strengthen long-term medicine security, the government is exploring several measures, including negotiating multi-year procurement agreements with suppliers, participating in joint purchasing initiatives with member countries of the Southern African Development Community (SADC), and streamlining administrative procedures to speed up the acquisition process.

The Ministry of Health reaffirmed that ensuring uninterrupted treatment remains its highest priority, particularly for cancer patients whose care depends on the continuous availability of life-saving medications.